Treasurys Turn Higher… And Novo Sinks After Trial Failure 7/31/26
About this episode
U.S. Treasurys popping to end the week as the 2 Year hits a near two-decade high and the 10 Year reaches highs not seen since January 2025. The traders break down the reason behind the surge and if this could affect the next Fed rate decision. Then, Novo Nordisk tumbling after a heart medicine trial failure. Mizuho securities healthcare sector specialist Jared Holz lays out how the company can coarse correct, and what this means for the broader pharmaceutical space. Plus, Amazon surging 15% on the back of its earnings while Exxon loses steam, and counting down to SpaceX’s earnings report as the aerospace giant trades well below its IPO price.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Get every episode summarized
Each time CNBC's "Fast Money" publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from CNBC's "Fast Money"
10-Year Yield Hits 19-Year High… And The Energy Outlook As Oil Surges 9/15/26
CNBC's "Fast Money"
Rates, Oil Rise As AI Warnings Sweep Wall St… And Banking On Blockchain 9/14/26
CNBC's "Fast Money"
Last Data Ahead Of Fed Decision… And Commemorating The 25th Anniversary Of 9/11...
CNBC's "Fast Money"
Oracle Reports Results… And Mortgage Rates Top 7% 9/10/26
CNBC's "Fast Money"